Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 4, 2001, Pages 377-380

  Shulman, Nancy S ^a   Machekano, Roderick A ^a   Shafer, Robert W ^a   Winters, Mark A ^a   Zolopa, Andrew R ^a   Liou, Song H ^b   Hughes, Michael ^b   Katzenstein, David A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Cross resistance; Drug resistance; Genotype; Stavudine; Zidovudine

Indexed keywords

RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONOTHERAPY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS LOAD; VIRUS MUTATION;

EID: 0035424029     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200108010-00008     Document Type: Article

References (22)

1. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
2. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
3. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
4. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
5. Resistance to ddi and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase
6. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2'′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
7. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy
8. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
9. Stavudine resistance: An update on susceptibility following prolonged therapy
10. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy
11. Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine
12. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
13. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
14. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
15. Virologic and CD4+ cell responses to new nucleoside regimens: Switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection
16. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
17. HIV-1 Pol
18. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements
19. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism
20. Removal of d4TMP from blocked primer/templates by HIV-1 reverse transcriptase-containing AZT-resistance mutations is strongly inhibited by physiological concentrations of DNTPS
21. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine